Work

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

Year: 2008
Type: article
Abstract: Following the initial success of imatinib as frontline therapy for chronic myeloid leukemia (CML), several second-generation therapeutics have been developed with increased potency and the ability to inhibit the majority of imatinib-resistant mutations. Here, we review the current knowledge about the target specificity of the two new inhibitors nilotinib and dasatinib in comparison to imatinib, including the recent large-scale chemical proteomics screens.
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: green
OpenAlex ID: W2034862875
FWCI: 9.512
Cites: 17
Cited by: 283
Related to: 10